The substrate iFeed is built on.
Curated writing across three operational domains — bioanalytical, bioequivalence, clinical trials — converging on the governance practice that surrounds them. Read across four audiences, four sub-areas, three domains, one focal point.
The library, as an open volume.
Closed spines · open spread · table of contents · chapterFour volumes on the shelf — bioanalytical, bioequivalence, methodology, and an AI lens. The Governance volume sits open in the middle: a table of contents on the left page, an excerpt from The QMS stack on the right. This is how the library reads — pick a volume, open it, read the chapter you came for.
Bioanalytical.
Method validation in the ICH M10 era. Analytical platforms, regulatory regimes, matrix types, method lifecycle. Nine BMV pillars across five regulators · the complete substrate iFeed is built on.
Bioequivalence.
80–125% bound. RSABE for highly variable drugs. NTI rules. BCS biowaivers (ICH M9). Reference product sourcing. Biosimilar PK. The regulator-facing spine of generic pathways.
Clinical trials.
ICH E6(R3) Step 4 (6 January 2025). EU CTR/CTIS. FDA DCT draft guidance (3 May 2023, still in draft as of 2026). Phase I–IV across nine GCP pillars · the full study lifecycle from start-up to closure.
Governance · Quality · QMS · Compliance.
The iFeed core. ISO 9001 · ICH Q9(R1) · ICH Q10 · QMSR (21 CFR 820) · ISO 13485 · ICH E6 R3 · ISO/IEC 42001. Eight binding standards in one stack · ALCOA+ data integrity · risk-based thinking · AI quality governance · the failure modes the practice exists to prevent.
The same lens across all four spaces.
Crystal City → ICH M10.
From the 1989 Bolar/Mylan generic-drug scandal to harmonised global text in 2022. Shah 1992 was the de facto standard for 8 years.
Read →Lindenbaum → ICH M13A.
One 1971 NEJM paper turned "same drug" into a PK question. Hatch-Waxman 1984 made BE the gatekeeper of the generic industry.
Read →Nuremberg → ICH E6 R3.
Nuremberg 1947 · Helsinki 1964 · Belmont 1979 · ICH-GCP 1996 · ICH E6(R3) Jan 2025 (principle-based GCP).
Read →ISO 9001 → ISO/IEC 42001.
ISO 9001 (1987) · ICH Q10 (2008) · QMSR (Feb 2026) · ISO/IEC 42001 (2023, the AI management system standard).
Read →ICH M10 v1 Step 4 May 2022 · adopted across ICH Regulatory Members.
2025 inspection-pattern themes (iFeed analysis of public 483s and Warning Letters): ISR sample selection ~28%, reagent-lot bridging ~22%, partial-validation gaps ~17%, method-transfer docs ~14%.
Read →80–125% bound, HV scaling divergence.
Universal TOST. RSABE: FDA permits reference-scaled BE on both AUC and Cmax; EMA permits widening only of Cmax to 0.6984–1.4319 with justified clinical rationale (AUC stays 80.00–125.00%). ANVISA Rules 2024 forced healthy-volunteer registry · medicamento de referência.
Read →E6 R3 · CTR · decentralised.
ICH E6(R3) in force 2025-2026 transition. EU CTR Reg (EU) 536/2014 fully applicable since 31 Jan 2022; CTIS mandatory 31 Jan 2023; legacy Directive 2001/20/EC trials transition completed 31 Jan 2025. FDA DCT draft guidance (3 May 2023, in draft as of 2026). India ICH Observer (CDSCO).
Read →QMSR effective Feb 2026.
21 CFR 820 harmonised with ISO 13485. Forces combination-product DHF-to-BMV bridges. EU AI Act high-risk classification 2026 onwards.
Read →M10 v2 by Q3 2028.
Tier 1/2/3 biomarker validation formalised. VCN sub-section. HRMS routinised by 2028. Reagent-lot bridging displaces ISR as #1 483.
Read →Complex generics · MIDD.
Long-acting injectables. Peptides. Drug-device combinations. PBPK as primary evidence by 2030s. Biosimilar interchangeability harmonisation.
Read →Decentralised + AI-augmented.
DCT mainstream by 2027. Synthetic control arms accepted by 2030 in select rare-disease contexts. Real-world evidence regulatory acceptance broadens.
Read →AI Act + ISO 42001.
EU AI Act high-risk full applicability 2026+. ISO/IEC 42001 becomes the AI-equivalent of ISO 9001. PCCP framework extends to bioanalytical AI by 2027.
Read →Peak detection · integration.
Production since 2018 in SCIEX, Waters, Shimadzu. ICH M10 v2 narrow scope: algorithm version + training data + validation set required.
Read →PBPK + virtual BE.
FDA 2024 MIDD permits PBPK as supportive for biowaivers. Full primary-evidence acceptance for selected complex generics projected 2030-2035.
Read →RBQM · eligibility.
Risk-based monitoring central. AI eligibility-screening triages enrolment. Synthetic control arms emerging. Generative-AI authoring still high-risk through 2030.
Read →EU AI Act + FDA PCCP.
Risk-tiered classification (high-risk / limited / minimal). Predetermined Change Control Plan lets locked AI models update post-market within pre-cleared envelope.
Read →10-step pipeline.
Method dev → pre-study validation → transfer → sample receipt → analysis → ISR → reanalysis → PK derivation → report → submission.
Read →12-step study lifecycle.
Protocol → site qualification → IRB → enrolment → dosing → sample collection → bioanalytical → PK statistics (TOST) → submission → inspection.
Read →12-step operational pipeline.
Concept → IND/CTA → protocol → SIV → recruitment → dosing → monitoring → DBL → CSR → submission. Each phase its own gating regime.
Read →Audit · inspection-readiness.
Q9(R1) 5-step risk lifecycle. CAPA loop (with effectiveness check). ALCOA+ data integrity. Audit-trail review (not just enabled). The cross-cutting governance routine.
Read →Selected writing from the archive.
The calibration curve.
Reading the calibration curve as the analytical method's autobiography. ±15% nominal except ±20% at LLOQ. What inspectors look for; what reports omit.
BA/BE trial flow · thirteen stages.
End-to-end flow: enquiry → feasibility → protocol → ethics → recruitment → conduct → bio-analysis → PK/stat → report → archive.
The bioanalytical trial flow.
Inside Stage 8. Three operational streams + two-mode QA layer. The architecture that produces the concentration data the regulator inspects.
Regulatory guideline comparison.
The 2020 sketch that grew into the 5-regulator / 9-pillar foundation document. The lineage of the current iFeed.bioanalytical reference.
Bioanalytical method validation · EMA.
Reading the EMA 2012 guideline through the lens of practitioner workflow. The predecessor to ICH M10 and the substrate the harmonised framework is built on.
Note for guidance on BA/BE.
Reading the EMA bioequivalence guideline carefully — what the BA half is doing for the submission, which subsections regulators emphasise.